ITC Probes Thyroid Meds Trade Rule Breaker
Published Date: 2/19/2025
Notice
Summary
The U.S. International Trade Commission is taking a second look at a decision that found a rule was broken involving certain thyroid medicine products. This affects companies making or selling these products and could lead to changes in how they're made or sold, possibly impacting costs and timing. The Commission wants feedback on how to fix the problem, protect the public, and handle money matters.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 0 costs, 2 mixed.
ITC to Review Section 337 Finding
The U.S. International Trade Commission is reviewing a final initial determination that found a violation of section 337 involving certain selective thyroid hormone receptor‑beta agonists, processes for making them, and products containing them. This review directly concerns companies that make or sell those drugs and related manufacturing processes.
Call for Comments on Remedy, Public Interest, Bonding
The Commission requests written submissions from parties, interested government agencies, and other interested persons on remedy, the public interest, and bonding in this matter. The request is part of the review process and asks stakeholders to provide views under the schedule set by the Commission.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in